Literature DB >> 11059733

Completion pneumonectomy of the residual left lung to treat lung cancer in a patient with hemophilia A: report of a case.

Y Nomoto1, H Kimura, N Iwai, T Mizobuchi, S Yokoi, K Kumagai.   

Abstract

Hemophilia A is a sex-linked recessive hereditary disease that is relatively rare and the number of patients with this disorder who undergo major surgery is limited. Although replenishing coagulation factors can allow hemophiliac patients to undergo similar surgery to that performed for patients without hemophilia, there have been few reports on major surgery and none on the resection of lung cancer in patients with hemophilia A. We recently performed completion pneumonectomy of the left lung in a 70-year-old man with hemophilia A, for squamous cell carcinoma in the residual left lung. The administration of a recombinant DNA coagulation factor VIII preparation allowed this operation to be successfully carried out. This case serves to demonstrate that the recombinant DNA coagulation factor VIII preparation described may enable us to safely perform major surgery on hemophiliac patients, since there is no risk of viral infection or any other adverse effects, such as deterioration of immunocompetence or hemolysis, which are occasionally encountered with human plasma-derived preparations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059733     DOI: 10.1007/s005950070045

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  11 in total

1.  Is major surgery in hemophiliac patients safe?

Authors:  W J Rudowski; R Scharf; J M Ziemski
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

2.  Hemolysis due to anti-A and anti-B in factor VIII preparations.

Authors:  R A Seeler
Journal:  Arch Intern Med       Date:  1972-07

3.  The experimental development of an ultrasonically activated scalpel for laparoscopic use.

Authors:  J F Amaral
Journal:  Surg Laparosc Endosc       Date:  1994-04

4.  Tissue actions of bipolar scissors compared with monopolar devices.

Authors:  M S Baggish; R D Tucker
Journal:  Fertil Steril       Date:  1995-02       Impact factor: 7.329

5.  [Clinical studies on surgeries in hemophilia--report of 7 cases].

Authors:  M Tomeoku; M Kuto; M Tsuda; T Nagano; H Wada; S Murashima; T Ito; K Deguchi; S Shirakawa
Journal:  Rinsho Ketsueki       Date:  1983-03

6.  Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

Authors:  R S Schwartz; C F Abildgaard; L M Aledort; S Arkin; A L Bloom; H H Brackmann; D B Brettler; H Fukui; M W Hilgartner; M J Inwood
Journal:  N Engl J Med       Date:  1990-12-27       Impact factor: 91.245

7.  The argon beam coagulator provides rapid hemostasis of experimental hepatic and splenic hemorrhage in anticoagulated dogs.

Authors:  P M Go; G R Goodman; E W Bruhn; J G Hunter
Journal:  J Trauma       Date:  1991-09

8.  Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs.

Authors:  M Wadhwa; P Dilger; J Tubbs; A Mire-Sluis; T Barrowcliffe; R Thorpe
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

9.  Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.

Authors:  H Fukui; A Yoshioka; M Shima; I Tanaka; K Koshihara; K Fukutake; M Fujimaki
Journal:  Int J Hematol       Date:  1991-10       Impact factor: 2.490

10.  Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.

Authors:  P M Mannucci; D B Brettler; L M Aledort; J M Lusher; C F Abildgaard; R S Schwartz; D Hurst
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

View more
  1 in total

1.  Free musculocutaneous flap transfer for refractory chronic empyema with chest wall sinus in a 43-year-old male with hemophilia A.

Authors:  Xiaowen He; Zhongliang He; Lifeng Shen; Guoxing Chen; Xueming He
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.